Vor Biopharma Inc (VOR)

Currency in USD
14.710
+0.860(+6.21%)
Closed·
14.504-0.207(-1.40%)
·
VOR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.66014.730
52 wk Range
2.62265.800
Key Statistics
Prev. Close
13.85
Open
13.85
Day's Range
13.66-14.73
52 wk Range
2.622-65.8
Volume
986.56K
Average Volume (3m)
994.37K
1-Year Change
11.2035%
Book Value / Share
-4.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VOR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
37.500
Upside
+154.93%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Vor Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 37.500
(+154.93% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy31.00+110.74%32.00MaintainApr 15, 2026
Stifel
Buy40.00+171.92%-MaintainApr 08, 2026
Jefferies
Buy48.00+226.31%50.00MaintainMar 30, 2026
Stifel
Buy40.00+171.92%55.00MaintainMar 30, 2026
Jefferies
Buy50.00+239.90%-New CoverageMar 29, 2026

Vor Biopharma Inc SWOT Analysis


AML Breakthrough
Vor Biopharma's trem-cel + Mylotarg combo shows promise in improving relapse-free survival for AML patients, with key data expected in 2025
Financial Runway
$91.9M cash position and $56M PIPE extend operations into Q1 2026, supporting critical clinical milestones despite negative EPS forecasts
Market Potential
Analyst price targets range from $5 to $18, reflecting significant upside potential in the competitive oncology therapeutics landscape
Strategic Expansion
Explore Vor's plans for a pivotal two-year controlled trial and potential applications of its technology beyond AML, diversifying its pipeline
Read full SWOT analysis

Earnings

Latest Release
Mar 30, 2026
EPS / Forecast
84.89 / -0.09
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

VOR Income Statement

Compare VOR to Peers and Sector

Metrics to compare
VOR
Peers
Sector
Relationship
P/E Ratio
−1.1x−3.5x−0.5x
PEG Ratio
0.01−0.100.00
Price/Book
−4.9x3.3x2.6x
Price / LTM Sales
-16.8x3.3x
Upside (Analyst Target)
188.8%158.2%47.1%
Fair Value Upside
Unlock5.9%6.2%Unlock

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren’s disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.14M3.95%29.61M
Other Institutional Investors
9.15M16.89%126.77M
Public Companies & Retail Investors
42.89M79.16%594.09M
Total
54.19M100.00%750.47M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
TCG Crossover Fund III, L.P.5.23%2,836,53939,286
FMR LLC4.66%2,526,17034,987

People Also Watch

9.25
KURA
+5.47%
57.62
KNSA
+4.25%
22.800
REP
+0.09%
34.18
STOK
+3.33%

FAQ

What Is the Vor Biopharma (VOR) Stock Price Today?

The Vor Biopharma stock price today is 14.710 USD.

What Stock Exchange Does Vor Biopharma Trade On?

Vor Biopharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Vor Biopharma?

The stock symbol for Vor Biopharma is "VOR."

What Is the Vor Biopharma Market Cap?

As of today, Vor Biopharma market cap is 797.070M USD.

What Is Vor Biopharma's Earnings Per Share (TTM)?

The Vor Biopharma EPS (TTM) is -70.502.

When Is the Next Vor Biopharma Earnings Date?

Vor Biopharma will release its next earnings report on Nov 07, 2025.

From a Technical Analysis Perspective, Is VOR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Vor Biopharma Stock Split?

Vor Biopharma has split 1 times.

How Many Employees Does Vor Biopharma Have?

Vor Biopharma has 76 employees.

What is the current trading status of Vor Biopharma (VOR)?

As of May 05, 2026, Vor Biopharma (VOR) is trading at a price of 14.710 USD, with a previous close of 13.850 USD. The stock has fluctuated within a day range of 13.660 USD to 14.730 USD, while its 52-week range spans from 2.622 USD to 65.800 USD.

What Is Vor Biopharma (VOR) Price Target According to Analysts?

The average 12-month price target for Vor Biopharma is 37.500 USD, with a high estimate of 50 USD and a low estimate of 15 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +154.93% Upside potential.

What Is the VOR Premarket Price?

VOR's last pre-market stock price is 13.768 USD. The pre-market share volume is 7,810.000, and the stock has decreased by -0.082, or -0.590%.

What Is the VOR After Hours Price?

VOR's last after hours stock price is 14.504 USD, the stock has decreased by -0.207, or -1.400%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.